Calls for papers
-
MannKind Corporation announced the initiation of the Phase 2 INFLO-2 trial of its MNKD-201 nintedanib DPI in patients with idiopathic pulmonary fibrosis. The 12-week INFLO-2 study is expected to enroll approximately 210 IPF patients who… Read more . . .
-
SoftOx Solutions announced the initiation of its Phase 1 SIS-02 study of SIS hypochlorous acid inhalation solution in healthy volunteers as part of a European Defense Fund-supported effort to develop the inhalation solution as a… Read more . . .
-
Scienture Holdings, which acquired US rights to Summit Biosciences’s Rezenopy naloxone nasal spray in March 2025, announced that the United States Patent and Trademark Office has granted Summit US Patent No. 12,622,903 B2 covering Rezenopy… Read more . . .
-
University of Glasgow spin-out Nebu~Flow has received a Scottish Enterprise grant worth £2 million “to accelerate development and patient access to its patented nebulizer technology in the UK and globally,” the company said. The company… Read more . . .
-
MannKind Corporation announced that the FDA has approved the company’s sBLA for use of Afrezza inhaled dry powder insulin for the treatment of Type 1 and Type 2 diabetes in children aged 6 and older. Afrezza was… Read more . . .
-
Jiangxi Kvvit Pharmaceutical is paying an undisclosed amount up front, plus potential milestones and royalties, to Merz Therapeutics to acquire the rights to develop and commercialize Merz’s Inbrija levodopa dry powder inhaler in mainland China,… Read more . . .
-
Australian biotech Rage Bio, which has been developing an inhaled splice-switching oligonucleotide (SSO) for the treatment of COPD, has announced that it has changed its name to Atisama Therapeutics. According to the announcement, the name… Read more . . .
-
According to Lupin, the FDA has tentatively approved the company’s ANDA for revefenacin inhalation solution, a generic of Mylan’s Yupelri inhalation solution. Yupelri was approved by the FDA for the treatment of COPD in 2018.… Read more . . .
-
Quince Therapeutics announced that it has agreed to acquire Orphai Therapeutics (formerly AI Therapeutics, formerly LAM Therapeutics) and its LAM-001 inhaled dry powder rapamycin (sirolimus) for $115 million up front and up to an additional… Read more . . .
-
More than a year after the FDA approved Satsuma’s Atzumi (STS 101) intranasal dry powder dihydroergotamine for the treatment of migraine in adults, Satsuma parent company SNBL says that it is still trying to find… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland